Filing Details

Accession Number:
0001104659-20-104436
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-09-11 16:31:30
Reporting Period:
2020-09-09
Accepted Time:
2020-09-11 16:31:30
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1001316 Tg Therapeutics Inc. TGTX Pharmaceutical Preparations (2834) 363898269
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1346824 Ra Capital Management, L.p. 200 Berkeley Street, 18Th Floor
Boston MA 02116
No No Yes No
1384859 Peter Kolchinsky C/o Ra Capital Management, L.p.
200 Berkeley Street, 18Th Floor
Boston MA 02116
No No Yes No
1619841 M. Rajeev Shah C/o Ra Capital Management, L.p.
200 Berkeley Street, 18Th Floor
Boston MA 02116
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2020-09-09 158,589 $25.81 12,629,868 No 4 S Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See footnote
Footnotes
  1. This transaction was executed in multiple trades at prices ranging from $25.66 to $26.08; the price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which these transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.
  2. These securities include 11,298,916 shares held by RA Capital Healthcare Fund, L.P. (the "Fund") and 1,330,952 shares held by a separately managed account (the "Account").
  3. RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and the Account. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members.
  4. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah may be deemed indirect beneficial owners of the reported securities for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the "Act"). They disclaim beneficial ownership of any of the reported securities for the purpose of determining whether they are subject to Section 16 of the Act, however, in reliance on Rule 16a-1(a)(1)(v) and (vii). To the extent that they might be deemed subject to Section 16, they disclaim beneficial ownership of securities held by the Fund for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein, and disclaim any pecuniary interest in securities held in the Account for purposes of Rule 16a-1(a)(2).